Health
EU Unveils Critical Medicines Act to Secure Drug Supply, But Key Questions Remain
The European Commission has introduced the Critical Medicines Act, a major initiative aimed at strengthening the EU’s access to essential medicines. The proposal, unveiled this week, seeks to reduce dependency on non-EU suppliers, enhance joint procurement, and encourage European production. However, questions remain over its funding, stockpiling strategy, and potential trade risks.
‘Buy European’ Proposal Raises Trade Concerns
One of the Act’s most debated measures is the ‘Buy European’ rule, which would prioritize suppliers manufacturing a significant portion of critical medicines within the EU. The goal is to ensure a more reliable drug supply, but critics warn that this protectionist approach could trigger retaliation from global trade partners.
EU Health Commissioner Olivér Várhelyi defended the policy, calling it “a necessary step for public health security.” However, comparisons have been drawn to China’s ‘Buy China’ policy, which the EU itself has criticized for restricting foreign suppliers. If the EU moves forward with this approach, it could face trade tensions and reduced market access abroad.
Boosting European Production Without Full Relocation
The proposal also aims to reduce reliance on non-EU pharmaceutical production by promoting increased manufacturing within Europe. However, rather than requiring production to be strictly within EU borders, the plan emphasizes bilateral partnerships with neighboring countries such as the UK, Switzerland, and EU candidate nations.
“I rely on our closest neighbors to help bring production closer to the EU,” said Várhelyi, suggesting that strategic supply chain diversification is the Commission’s preferred approach over full relocation.
Funding Challenges Could Limit Impact
A key concern surrounding the Act is funding constraints. The Commission has allocated €83 million for 2026-2027, primarily from the EU4Health program. However, this budget is too small to support large-scale manufacturing shifts, raising doubts about the proposal’s effectiveness.
While additional funding could come from Horizon Europe and the Digital Europe Programme, 11 EU health ministers have called for defense funding to include medicine production, an idea that Várhelyi rejected. Instead, the Commission is loosening state aid restrictions, encouraging member states to fund production efforts themselves.
Strengthening Joint Drug Procurement
To improve purchasing efficiency, the Act enhances the EU’s joint procurement mechanism. Traditionally, the Commission and at least nine member states negotiate as a single bloc to secure better pricing and supply terms. The new proposal expands this approach, allowing the Commission to act as a central buyer upon request.
Additionally, a cross-border procurement model will be introduced, where the Commission provides logistical and administrative support to individual member states handling their own drug purchases.
Stockpiling Strategy Left Out
One of the biggest gaps in the proposal is the lack of a coordinated stockpiling framework. The Critical Medicine Alliance had recommended a harmonized EU-wide contingency stock, ensuring member states share supplies during shortages.
However, this was omitted from the final proposal, sparking concerns of fragmented and inequitable stockpiling across the bloc. Croatian MEP Tomislav Sokol warned that larger countries hoarding supplies at the expense of smaller nations must not happen again.
What’s Next?
As the Critical Medicines Act moves into the legislative process, MEPs are expected to push for amendments, particularly to address stockpiling coordination and funding gaps. While the proposal marks a major step toward securing Europe’s medicine supply, unresolved questions could shape its final impact in the coming months.
Health
Global Mental Health Cases Near 1.2 Billion as Anxiety and Depression Drive Sharp Worldwide Rise
A major global analysis has found that mental health conditions have surged to an estimated 1.2 billion people worldwide, driven largely by steep increases in anxiety and depression over the past three decades.
The findings, published in The Lancet as part of the Global Burden of Disease Study 2023, show that the number of people living with mental disorders has almost doubled since 1990, marking a 95% rise. Researchers say major depressive disorder and anxiety disorders have seen even sharper growth, increasing by 131% and 158% respectively, making them the most prevalent mental health conditions globally.
The report describes mental illnesses as widespread conditions that create long-term disability and significant human suffering. It also highlights broader consequences for economies and public services, including reduced productivity, lower workforce participation and increasing pressure on health and welfare systems.
Researchers estimate that in 2023 alone, around 620 million females and 552 million males were affected by mental health conditions. While the overall burden is rising across both sexes, the study points to notable differences in the types and prevalence of disorders.
Among women, depression and anxiety were the most commonly reported conditions, alongside higher rates of eating disorders such as anorexia nervosa and bulimia nervosa. The report links this disparity to a mix of biological, social and structural factors, including exposure to domestic violence, sexual abuse, gender inequality and reproductive health-related changes.
In contrast, neurodevelopmental and behavioural disorders, including attention deficit hyperactivity disorder (ADHD), conduct disorder and autism spectrum conditions, were more frequently diagnosed in men.
Teenagers aged 15 to 19 were identified as the group experiencing the highest mental health burden globally, raising concerns about early onset of conditions and insufficient preventive care for young people.
The study identifies several key risk factors associated with mental illness, including childhood sexual violence, bullying and intimate partner violence. These factors are strongly linked to conditions such as depression, schizophrenia, bipolar disorder and anxiety disorders. However, researchers note that such exposures have remained relatively stable over time and account for only a portion of the overall rise.
According to the authors, broader drivers are likely contributing to the increasing prevalence of mental disorders. These include genetic and biological influences, poverty, inequality, and the growing impact of global crises such as armed conflict, pandemics, natural disasters and climate-related stress.
While mental health conditions have long been a leading cause of disability worldwide, the report warns that the situation is worsening. At the same time, health systems have not expanded services at a pace matching demand.
The authors caution that the gap between rising need and limited access to care is becoming more pronounced, leaving millions without adequate treatment or support.
Health
Europe Records Sharp Rise in Sexually Transmitted Infections, ECDC Warns
Health
White House Rejects Report It Blocked Return of Ebola-Infected US Doctor
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
